New treatments for metastic prostate cancer.
The FDA has approved 2 new treatments for castration-resistant (formerly called hormone-refractory) prostate cancer. Sipuleucel-T (Provenge - Dendreon) s the first immunotherapy approved for treatment of prostate cancer. Cabazitaxel (Jevtana - Sanofi-Aventis) is approved for second-line treatment of metastatic castration-resistant prostate cancer previously treated with docetaxel (Taxotere).
D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D004347:Drug Interactions; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D043823:Taxoids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014020:Tissue Extracts / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*
D019496:Cancer Vaccines; D043823:Taxoids; D014020:Tissue Extracts; C552428:cabazitaxel; C511774:sipuleucel-T